Mutation-Selective IDH2 Inhibitors for 2HG-Driven Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Mutant IDH2 enzymes in certain cancer cells exhibit a new ability to catalyze the NADPH-dependent reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate, contributing to cancer formation and progression, necessitating the development of inhibitors to target this neoactivity.
Innovation Solution
Development of compounds that inhibit the mutant IDH2 enzyme's ability to catalyze the reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate, specifically targeting IDH2 R140Q or R172K mutations, which are used in pharmaceutical compositions to treat cancers such as glioblastoma, myelodysplastic syndrome, and acute myelogenous leukemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mutant IDH2 enzyme is left untreated, then cancer cells can utilize the enzyme's neoactivity to produce 2HG and promote tumor progression, but developing specific inhibitors requires precise targeting of the mutated enzyme without affecting wild-type IDH2 function
Solution Approach 1:
The patent applies local quality by designing inhibitors that specifically target the mutant IDH2 enzyme's unique active site conformation caused by specific mutations (R140Q, R172K, R172L). The inhibitors are structured to bind selectively to the altered enzyme form while preserving wild-type IDH2 function, achieving mutation-specific inhibition through localized chemical interaction with the mutated residue regions.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of IDH2 inhibitors based on the specific mutation type. Different mutations (R140Q vs R172K vs R172L) result in tailored inhibitor structures with adjusted molecular properties to optimize binding affinity and selectivity for each mutant variant, allowing precise control over inhibition parameters.
2Adaptability or versatility
If broad-spectrum IDH2 inhibitors are used, then multiple cancer types with IDH2 mutations can be treated, but the inhibitors may also inhibit wild-type IDH2 and cause unwanted side effects
Solution Approach 1:
The patent applies local quality by designing inhibitors that specifically target the mutant IDH2 enzyme's unique active site conformation caused by specific mutations (R140Q, R172K, R172L). The inhibitors are structured to bind selectively to the altered enzyme form while preserving wild-type IDH2 function, achieving mutation-specific inhibition through localized chemical interaction with the mutated residue regions.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of IDH2 inhibitors based on the specific mutation type. Different mutations (R140Q vs R172K vs R172L) result in tailored inhibitor structures with adjusted molecular properties to optimize binding affinity and selectivity for each mutant variant, allowing precise control over inhibition parameters.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit the mutant IDH2 enzyme's neoactivity, potentially reducing elevated levels of 2HG and slowing or arresting the progression of associated cancers.
Implementation Method 1
mutations of IDH2 present in certain cancer cells result in a new ability of the enzyme to catalyze the NADPH-dependent reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2HG)
Implementation Method 2
the NADPH-dependent reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate
Data Source
AI summary
Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.